View More Recent Stories

Jan 10, 2025 07:01AM BioCryst Pharma (BCRX) Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437
Nov 4, 2024 02:20PM BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
Nov 4, 2024 02:16PM BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
Nov 4, 2024 07:04AM BioCryst Pharma (BCRX) Reports In-Line Q3 EPS ; Offers Guidance
Oct 14, 2024 07:01AM BioCryst Pharma (BCRX) to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO
Oct 10, 2024 07:01AM BioCryst Pharma (BCRX) to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO
Oct 2, 2024 07:03AM BioCryst Pharma (BCRX) Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
Sep 30, 2024 07:00AM BioCryst Pharma (BCRX) Wins US Govt's $69M RAPIVAB Contract for Strategic National Stockpile
Sep 17, 2024 07:06AM BioCryst Pharma (BCRX) and pCPA Successfully Complete Negotiations for ORLADEYO
Sep 6, 2024 05:02AM BioCryst Pharma (BCRX) Presents New ORLADEYO Data
Sep 5, 2024 07:01AM BioCryst Pharma (BCRX) Appoints Donald Fong as Chief Medical Officer
Aug 7, 2024 10:00AM Eight defensive growth stocks to own right now
Aug 5, 2024 04:01PM BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
Aug 5, 2024 07:02AM BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance
Jul 21, 2024 06:00AM 10 policies if Trump wins and stock implications: Jefferies
Jul 9, 2024 07:00AM BioCryst Pharma (BCRX) Announces ORLADEYO Approved in Peru
Jun 25, 2024 10:31AM TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)
View More Recent Stories